Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

An Exploratory Study Comparing Two Nicotine Inhalers

6 juli 2012 bijgewerkt door: McNeil AB

A Proof of Concept With a New Nicotine Inhaler in Comparison With Nicotine Inhaler 10 mg

Subjects will be screened within 28 days before the first study treatment to confirm that they meet the requirements to participate in the trial. They will return to the site for two treatment visits, at least 12 hours each, and at least one day in between visits. At each visit treatment N1/3-I5 or Nicotine Inhaler 10 mg will be administered every hour for 11 hours. The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject. Blood samples will be drawn on a special schedule. The total predicted amount of blood sampled from each subject is 174 mL over the whole study. Subjects will be required to follow specific smoking and dietary restrictions and rate their urges to smoke, general liking of the product, and how easy the product is to use.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Blood for pharmacokinetic analyses will be drawn prior to the first administration and immediately before administration at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 hours. Thereafter samples will be drawn at 5, 10, 15, 20, 25, 30, 45, and 60 minutes after the 11-hour administration. Easiness of use will be rated using an 8-grade ordered category scale at 10 minutes after the start of administrations at 3, 6, and 9 hours. Overall liking will be rated using an 8-grade ordered category scale at 12 hours. Urges to smoke will be rated on a 4-grade ordered category scale immediately before and at 15 minutes after the first administration, and as well as before and 15 minutes after the start of administrations at 3, 6, and 9 hours, and at 12 hours. Used cartridges will be collected. Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).

Since the primary objective is to compare steady-state nicotine pharmacokinetics of N1/3-I5 with that of Nicotine Inhaler 10 mg, this study will have a multiple-dose setting. A crossover design has been chosen for this study in order to allow within-subject comparisons of treatments. Healthy habituated adults smoking at least 10 cigarettes daily for at least one year preceding inclusion will be included in the study, since they are expected to tolerate the doses of nicotine that will be administered.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

36

Fase

  • Vroege fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Zweden
      • Lund, Zweden, 222 20
        • McNeil AB Clinical Pharmacology R&D

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Healthy (per protocol-specified parameters) male or female subjects between the ages of 19 and 50 years, inclusive.
  • Smoking of at least 10 cigarettes daily during at least one year preceding inclusion.
  • For females: Postmenopausal state or premenopausal/perimenopausal state with a protocol-specified effective means of contraception or declared absence of sexual contact with a male partner during the study.
  • For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
  • Body Mass Index (BMI) within protocol-specified parameters.
  • A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol

Exclusion Criteria:

  • Evidence or history of an acute or chronic medical or psychiatric condition or allergy or laboratory abnormality, or of use of drugs that, in the judgment of the investigator or an authorized study physician, may increase the risk associated with study participation or interfere with the interpretability of study results.
  • Females: Pregnancy, breast-feeding, premenopausal, or perimenopausal, state with insufficient contraception as specified under Inclusion Criteria.
  • Males: Pregnant spouse or partner or no willingness to prevent conception in a spouse or partner.
  • History of regular alcohol consumption outside the protocol-specified allowances.
  • Treatment with an investigational drug within 3 months preceding the first dose of study treatment.
  • Known sensitivity to heparin or history of heparin-induced thrombocytopenia.
  • Pathological oral status interfering with normal muscular, sensory, or absorptive function of the oral cavity. Piercing of tongue and lips is considered to impair oral function.
  • Relationship to persons involved directly with the conduct of the study, or their families.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: N1/3-I5
5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
Geneesmiddel: Nicotine
Nicotine 5 mg Inhaler
Andere namen:
  • Nog niet op de markt gebracht
Geneesmiddel: Nicotine
Nicotine 10 mg Inhaler
Andere namen:
  • Nog niet op de markt gebracht
Actieve vergelijker: NX-I10
10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
Geneesmiddel: Nicotine
Nicotine 5 mg Inhaler
Andere namen:
  • Nog niet op de markt gebracht
Geneesmiddel: Nicotine
Nicotine 10 mg Inhaler
Andere namen:
  • Nog niet op de markt gebracht

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maximum Observed Plasma Concentration (Cmax)
Tijdsspanne: During last dosing interval 11-12 hours post-dose
Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)
During last dosing interval 11-12 hours post-dose
Average Concentration (Cav)
Tijdsspanne: During last dosing interval 11-12 hours post-dose

The average concentration of nicotine in the blood.

* The dosing interval (τ) in this study will be one (1) hour. Consequently, Cav will have the same value as AUCτ (but with a different unit), since Cav is calculated as AUCτ divided by τ. Therefore Cav will not be displayed in results, only AUCτ.
During last dosing interval 11-12 hours post-dose
Bioavailability [AUCτ]
Tijdsspanne: During last dosing interval 11-12 hours post-dose
AUCτ is the area under the plasma concentration-vs.-time curve during the last dosing interval and is a measure of how much of the drug reaches the person's bloodstream. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve is calculated as hour * nanograms (ng) per milliliter (mL).
During last dosing interval 11-12 hours post-dose

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Minimum Observed Plasma Concentration (Cmin)
Tijdsspanne: During last dosing interval 11-12 hours post-dose
Minimum Observed Plasma Concentration (Cmin), which is the minimum concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)
During last dosing interval 11-12 hours post-dose
Time of Maximum Concentration (Tmax)
Tijdsspanne: During last dosing interval 11-12 hours post-dose
The time at which maximum concentration is reached (Tmax)
During last dosing interval 11-12 hours post-dose
Peak Trough Fluctuation (PTF)
Tijdsspanne: During last dosing interval 11-12 hours post-dose
Peak trough fluctuation within one dosing interval at steady state.
During last dosing interval 11-12 hours post-dose
Swing
Tijdsspanne: During last dosing interval 11-12 hours post-dose
Swing within one dosing interval at steady state.
During last dosing interval 11-12 hours post-dose
Baseline-corrected Pre-Dosing Plasma Concentration (Cn)
Tijdsspanne: 0 Minutes
Baseline-corrected nicotine plasma concentrations immediately before each user session (Cn)
0 Minutes
Residual Nicotine
Tijdsspanne: 12 hours
Used cartridges will be collected. Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine.
12 hours
Urges to Smoke
Tijdsspanne: During 12 hours
Subjects will rate their urges to smoke on a category scale from 1 to 4, where 1= No or very light urge to smoke, and 4= Very strong or extreme urge to smoke.
During 12 hours
Overall Liking
Tijdsspanne: at 12 hours
Overall Liking will be rated on a category scale from 1 to 8, where 1= extremely good and 8=extremely bad.
at 12 hours
Ease of Use
Tijdsspanne: During 9 hours
Ease of use will be rated at specific categorical time points, on a scale of 1-8, where 1= extremely easy and 8=extremely hard..
During 9 hours

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

McNeil AB

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 november 2011

Primaire voltooiing (Werkelijk)

1 december 2011

Studie voltooiing (Werkelijk)

1 december 2011

Studieregistratiedata

Eerst ingediend

21 november 2011

Eerst ingediend dat voldeed aan de QC-criteria

21 november 2011

Eerst geplaatst (Schatting)

23 november 2011

Updates van studierecords

Laatste update geplaatst (Schatting)

10 juli 2012

Laatste update ingediend die voldeed aan QC-criteria

6 juli 2012

Laatst geverifieerd

1 juli 2012

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NICTDP0002
  • 2011-002796-41 (EudraCT-nummer)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren